Grantham, Mayo, Van Otterloo & Co (GMO)’s Amicus Therapeutics FOLD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Buy	+941,266	New	+$13.5M	0.03%	217

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s FOLD Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 941,266 shares worth $13.6M. The stake represents 0.03% of the portfolio and ranks #217 among its holdings.

298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 941,266 shares of Amicus Therapeutics worth $13.6M as of Q1 2026.
Amicus Therapeutics was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q1 2026.
Amicus Therapeutics made up 0.03% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #217 holding.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.